On Friday, Alaska Air Group, Inc. (NYSE:ALK)’s shares inclined 2.72% to $63.50.
Alaska Air Group, Inc. (ALK) named practiced Information Technology executive David Kuhl its new vice president of IT services.
Kuhl has more than 30 years of experience in the field of IT, most as vice president of Corporate IT at Expedia where he led technology for contact centers, financial systems, HR and collaboration, in addition to end-user services. Prior to his six years at Expedia, Kuhl led IT teams at Microsoft and AT&T Wireless/Cingular Wireless, and has worked at Boeing, General Dynamics and Arizona State University.
At Alaska, Kuhl will be responsible for all IT services and more than 80 employees, assisting to drive a culture of continual learning and superior customer service. He will oversee the departments of field services, service desk and production operations, infrastructure engineering, IT services performance administration and network connectivity.
Alaska Air Group, Inc., through its auxiliaries, provides passengers and cargo air transportation services primarily in the United States. The company operates through Alaska Mainline and Alaska Regional segments.
AirMedia Group Inc (ADR) (NASDAQ:AMCN)’s shares gained 3.86% to $7.26.
AirMedia Group Inc (ADR) (AMCN) declared that Guangzhou Meizheng Advertising Co., Ltd. (“Meizheng”), one of its merged entities in which AirMedia has 63.2% of the equity interest, has recently obtained the exclusive right to install and operate Wi-Fi systems on ordinary trains operated by Beijing Railway Bureau. As of the time of execution of the concession agreement, Beijing Railway Bureau had 89 groups of ordinary trains in operation.
Other than the aforementioned concession right, Meizheng also holds the concession rights to exclusively install and operate Wi-Fi systems on the high-speed trains operated by Beijing Railway Bureau.
AirMedia Group Inc. operates out-of-home advertising platforms primarily in the People’s Republic of China. The company operates a network of digital TV screens on planes operated by seven airlines; traditional media in airports, such as light boxes, billboards, and painted advertisements; and gas station media displays, in addition to other outdoor media displays out of the air travel advertising sector.
At the end of Friday’s trade, CDK Global Inc (NASDAQ:CDK)‘s shares dipped -1.21% to $50.62.
CDK Global Inc (CDK) declared that it will host an Investor Day on June 16, 2015 in Chicago. The event will be webcast live from 10:00 a.m. to 12:30 p.m. CT and can be accessed together with summary presentation materials at CDK’s website at http://investors.cdkglobal.com. CDK’s market-leading solutions will be showcased at demo booths one hour before the conference starts and one hour after the conclusion of the conference.
CDK Global, Inc. provides integrated information technology and digital marketing/advertising solutions to the automotive retail industry. Its solutions automate and integrate critical workflow processes from pre-sale targeted advertising and marketing campaigns to the sale, financing, insurance, parts supply, and repair and maintenance of vehicles. The company serves about 26,000 retail locations and automotive manufacturers in about 100 countries. CDK Global, Inc. is headquartered in Hoffman Estates, Illinois.
Array Biopharma Inc (NASDAQ:ARRY), ended its Friday’s trading session with -2.20% loss, and closed at $7.56.
Array Biopharma Inc (ARRY) was showcased at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO). At the meeting, preliminary data for the combination of binimetinib and encorafenib from a Phase 1b/2 dose escalation and expansion study in patients with BRAF-mutant melanoma who are BRAF inhibitor treatment naive were shared during an oral presentation. Results from the study indicate that binimetinib and encorafenib may be safely combined and show encouraging clinical activity comprising with MEK/BRAF inhibitor expectations in patients with BRAF-mutant melanoma who are BRAF inhibitor treatment naive. In addition, a differentiated safety profile relative to other MEK/BRAF inhibitor combinations is emerging in the dose range presently being used in the Phase 3 COLUMBUS trial. Array anticipates updated BRAF melanoma data from the ongoing Phase 2 combination trial (LOGIC-2) of binimetinib and encorafenib followed by the addition of a third targeted agent identified based on genetic testing at the time of progression will be presented to a scientific conference later this year. LOGIC-2 utilizes the same dose of binimetinib and encorafenib presently being studied in the COLUMBUS trial.
Preliminary data from the study also indicate that in combination with binimetinib, encorafenib was tolerated at doses up to 600 mg, twice its single-agent maximum tolerated dose. At the 400/450 mg dose of encorafenib, with few grade 3 / 4 events and an 11 percent incidence of pyrexia and photosensitivity, a differentiated safety profile relative to other MEK/BRAF inhibitor combinations is emerging.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s products in Phase III clinical trials comprise Binimetinib and Encorafenib for the treatment of cancer. Its clinical programs in Phase II clinical trial comprise ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.